(thirdQuint)Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma.

 OBJECTIVES: - Determine the safety and efficacy of forodesine (BCX-1777) in patients with refractory stage IIA-IVB cutaneous T-cell lymphoma.

 - Determine the pharmacokinetics and pharmacodynamics of this drug in these patients.

 OUTLINE: This is an open-label, multicenter study.

 Patients receive oral forodesine (BCX-1777) once daily on days 1-28.

 Courses may be repeated in the absence of disease progression or unacceptable toxicity.

 Patients are followed periodically.

 PROJECTED ACCRUAL: Not specified.

.

 Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma@highlight

RATIONALE: Forodesine (BCX-1777) may stop the growth of cancer cells by blocking the enzymes necessary for their growth.

 PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory stage IIA, stage IIB, stage III, stage IVA, or stage IVB cutaneous T-cell lymphoma.

